Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2013-04-29 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Share Purchase Plan 2 pages 109.0KB
Capital/Financing Update Classification · 100% confidence The document is an announcement of a Share Purchase Plan (SPP) by Imugene Limited, detailing the offer to existing shareholders to subscribe for new shares, the use of funds, key dates, and contact information. It does not contain financial statements, detailed financial analysis, or regulatory filings but rather focuses on capital raising activity and share issuance details. The document length is under 5,000 characters and reads as a formal announcement rather than a full report. Therefore, it fits the category of Capital/Financing Update (CAP).
2013-04-29 English
Share Purchase Plan - Offer Document 21 pages 385.5KB
Report Publication Announcement Classification · 85% confidence The document text is heavily redacted or encrypted, but it contains multiple references to regulatory and financial terms such as 'Annual Report', 'financial statements', and 'report publication'. The text also includes phrases like 'report is attached', 'has been published', and references to report availability, which suggests this is an announcement rather than the full report itself. The document length is 15,000 characters, which is substantial, but the content appears to be more about announcing or referencing a report rather than containing detailed financial data or analysis. There are no clear indications of it being a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The presence of phrases indicating report availability aligns with the definition of a Report Publication Announcement (RPA). Therefore, the most appropriate classification is Report Publication Announcement (RPA).
2013-04-29 English
Appendix 4C - quarterly 5 pages 156.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The presence of quarterly financial data and the nature of the report align with a comprehensive interim or quarterly financial report. The document length is 7439 characters, which is sufficient to contain substantive financial data rather than just an announcement or certification. The document is not a full annual report, audit report, or earnings release but a quarterly report with actual financial statements and analysis. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q3 2013
2013-04-28 English
Imugene to be awarded Japanese patent 2 pages 157.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the acceptance of a Japanese patent application for Imugene's novel drug delivery technology. It discusses the patent application, the technology, and its potential commercial applications. There is no financial data, regulatory filing, or report attached or referenced. The content is an announcement related to intellectual property and technology development, not a financial report, management change, or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) since it is a corporate announcement that does not fit other specific categories.
2013-03-04 English
Half Yearly Report and Accounts 24 pages 1.4MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4D For the Half Year Ended 31 December 2012' and contains detailed financial statements including a Directors' Report, Auditor's Independence Declaration, Consolidated Statement of Profit or Loss and Other Comprehensive Income, and other financial data for the half-year period ending 31 December 2012. It includes comprehensive financial information and analysis for a period shorter than a full fiscal year, which matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2013
2013-02-27 English
Half Year Financial Results 2 pages 111.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Half Year Financial Results' and provides detailed financial and operational information for the six months ended 31 December 2012. It includes financial figures such as cash reserves, revenues, and net loss, as well as business updates on drug development and management changes. The content is comprehensive and covers a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 4441 characters, which is sufficient to contain substantive financial data and analysis, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2013
2013-02-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.